Recent Updates
Recently added Catalysts
BBIO Positive Sentiment Score: 70/100

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Wednesday, September 3, 2025 2 min read
Key Takeaway: BridgeBio Pharma is set to host an investor webinar on September 10, 2025, focusing on autosomal dominant hypocalcemia type 1 (ADH1). Dr. Rachel Gafni from the NIH will discuss the disease's pathophysiology and the ongoing Phase 3 CALIBRATE clinical trial, which is currently evaluating the treatment encaleret. The webinar aims to address current unmet needs in ADH1 and expectations surrounding the clinical study's topline results expected later this year.

Market Sentiment Analysis

POSITIVE FACTORS

  • BridgeBio is hosting an informative investor webinar focusing on ADH1.
  • Dr. Rachel Gafni will provide insights from her expertise at NIH.
  • Discussion of Phase 3 clinical trial CALIBRATE could attract investor interest.
  • Topline results expected in fall 2025 may signal potential for treatment advancement.

Full Press Release Details

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company’s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1).
Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1.
In addition to Dr. Gafni, executive members of the ADH1 program team will review the ongoing encaleret clinical development program and discuss the ongoing Phase 3 CALIBRATE study, for which topline results are expected in fall 2025.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance

Frequently Asked Questions

When is the BridgeBio investor webinar scheduled?

The investor webinar is set for Wednesday, September 10, 2025, at 8:00 am ET.

Who will lead the webinar discussion on ADH1?

Dr. Rachel Gafni, a Senior Research Physician at NIH, will lead the discussion.

What is the focus of the CALIBRATE clinical trial?

The CALIBRATE trial evaluates encaleret as a treatment for autosomal dominant hypocalcemia type 1.

How can I access the webinar and its replay?

Visit the 'Events & Presentations' page on the BridgeBio website to access the webinar.

When will topline results from the CALIBRATE study be available?

Topline results from the CALIBRATE study are expected in fall 2025.

Tags: BBIO Viatris Investor Conferences Healthcare BridgeBio ADH1 clinical trial encaleret Phase 3
Last updated: Sep 3, 2025